Codiak BioSciences Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$168.5M
Industry:Biotech
Founded:2015
Lead Investor(s):ARCH Venture Partners, Flagship Ventures

Industry Ranking

Estimated Revenue & Financials

  • Codiak BioSciences's estimated annual revenue is currently $16.3M per year.
  • Codiak BioSciences received $76.5M in venture funding in November 2017.
  • Codiak BioSciences's estimated revenue per employee is $155,000
  • Codiak BioSciences's total funding is $168.5M.

Employee Data

  • Codiak BioSciences has 105 Employees.
  • Codiak BioSciences grew their employee count by 59% last year.
  • Codiak BioSciences currently has 2 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

Codiak is the leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines. A venture-backed startup founded in 2015, Codiak has rapidly built a proprietary technology platform for exosome engineering and manufacturing that allows for precise targeting of important molecular pathways, opening the door to the development of therapies for cancer and other diseases. Led by an experienced and dedicated team, Codiak has at its foundation a positive and collaborative culture that is deeply rooted in cutting edge science and promotes opportunity for growth. Recent discoveries have transformed our understanding of the role of exosomes in the body. We now know that these natural, cell-derived vesicles can act as a potent and safe delivery system for multiple therapeutic payloads. Recognizing the enormous potential of exosomes, Codiak is applying leading-edge translational science and rigorous drug development to build a pipeline of candidates with broad utility and the capacity to address currently undruggable targets. While our initial focus is on oncology/immuno-oncology, this approach also offers significant potential in hematology, neurology and gene therapy and other therapy areas. At Codiak, we are working to create a major shift in the development of tomorrow's medicines through scientific ambition, remarkable ingenuity and deep passion for improving patients lives. Located in the heart of Boston's biotechnology hub in Cambridge, Massachusetts, we are advancing a bold vision by tapping into the unique talents of a varied pool of individuals who together are achieving truly exceptional work. Come Join Us.

keywords:Biotechnology,Healthcare,Pharmaceuticals

105

Number of Employees

$16.3M

Revenue (est)

2

Current Jobs

59%

Employee Growth %

$168.5M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Richard BrudnickChief Business Officer And Head Of StrategyEmail Available
Mark ScuzzarellaHuman Resources DirectorEmail Available
Nuruddeen LewisAssociate Director, Cellular Immuno-oncologyEmail Available
Joon Chong YeeAssociate Director, Upstream Process DevelopmentEmail Available
Jorge Sanchez-SalazarPrincipal Associate ScientistEmail Available
Andrew GrubePrincipal Research AssociateEmail Available
Bryan Young Jun ChoiPrincipal Research Associate
Joanne GibbonsVice President Regulatory AffairsEmail Available
Kate WeissVice President, Investor Relations and Communications
Cara LowenVice President And Chief Patent CounselEmail Available

Codiak BioSciences News

09/05/2019 - Exosome diagnostics and therapeutics Market Research ...

Codiak BioSciences, Evox Therapeutics Ltd., Exosome Diagnostics Inc., HansaBioMed Life Sciences Ltd. (Lonza), NonoSomiX Inc., and ...

09/06/2019 - Stem Cell Exosomes Market Research Report Analysis And ...

Takara Bio Company, Illumina Inc, Thermo Fisher Scientific Inc, Codiak BioSciences, Evox Therapeutics Limited, HansaBioMed Life Sciences, ...

07/30/2019 - Codiak BioSciences Expands Executive Leadership Team to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Codiak BioSciences Inc., a company pioneering exosomes as a new class of biologic medicines, ...

Codiak BioSciences Funding

DateAmountRoundLead InvestorsReference
2015-11-18$80.0MUndisclosedARCH Venture PartnersArticle
2016-01-27$61.0MBARCH Venture PartnersArticle
2017-11-30$76.5MCMultipleArticle

Codiak BioSciences Executive Hires

DateNameTitleReference
2015-11-18Douglas E. WilliamsFounding President/CEOArticle
2016-01-06Ariel Jasiechief business officerArticle
2016-05-18Jan LötvallChief ScientisArticle
2016-10-14Benny SorensenVP/Head Of Clinical DevelopmentArticle
2018-06-05Richard BrudnickChief Business Officer and Head of Strategy.Article
2018-09-12Robert BrennerEVP/Head of Research & DevelopmentArticle
2019-02-21Andrea DiFabioChief Legal OfficerArticle